ISCPh: CLINICAL CANNABIS PHARMACIST CONFERENCE AGENDA

THURSDAY, AUGUST 13, 2020

12 PM – 2 PM: General registration begins for tours – Please arrive before 15 min before scheduled departure time to ensure a timely departure 

2 PM – 630 PM: Optional Accedited Tours
(Note: time may change to 1230-530 PM based on traffic conditions)

Examine the required components that make Cannabis medical

  1. Observe the process to maintain pharmaceutical grade medicine
  2. Outline testing standards that ensure consistent and reliable products
  3. Explain potential contaminants during various stages of medical Cannabis production
  4. Summarize operating procedures for safe handling of Cannabis products to prevent diversion
  5. Compare FDA recall classes to Cannabis industry recall practices
  6. Illustrate the need for HIPAA-compliant record keeping requirements in medical dispensaries
  7. Review product labeling to determine chemical composition, concentration, and calculate days supplied

5 PM – 9 PM: General registration

7 PM – 9 PM: Optional: Dinner with tour attendees and speakers 

 

FRIDAY, AUGUST 14, 2020

7 AM – 8 AM: Registration and Breakfast

745 AM – 9 AM: Endocannabinoids with Dr. Dustin Sulak, DO    

Discover the structure and function of the Endocannabinoid System (ECS)

  1. Identify the principle mediators of the ECS
  2. Examine the functions of the Endocannabinoid system (ECS)
  3. Explain the theory of Clinical Endocannabinoid Dysfunction (CECD)

9 AM – 945 AM: Phytocannabinoids with Dr. Linda Klumpers, PhD

Analyze the pharmacological and pharmacokinetic properties of major cannabinoids

  1. Compare the structure and function of major and minor cannabinoids including THC, CBD, CBN, CBG, CBC, and THCV
  2. Explore the role of the entourage hypothesis including the role of terpenes and flavonoids
  3. Summarize the pharmacodynamics effects of major and minor cannabinoids
  4. Examine the varying onset and duration of commonly available formulations

 

945 AM – 1015 AM: PK/PD Drug Interactions with Dr. Christine Roussel, PharmD, BCOP

Determine clinically relevant drug-drug and drug-disease interactions

  1. Summarize the CYP P450 pathways for major and minor cannabinoids
  2. Identify clinically relevant drug-drug and drug-disease interactions with cannabinoids; THC and CBD
  3. Recommend strategies to manage drug-drug and drug-disease interactions with medical Cannabis products

1015 AM – 1045 AM: Exhibitor Break  

1045 AM – 1145 AM: Cannabis in Cancer Care with Dr. Donald Abrams, MD  

Evaluate the use of Cannabis medicine in palliative care

  1. Identify potential uses of Cannabis medicine during Cancer care
  2. Review information regarding the use of Cannabis as an anti-cancer agent 
  3. Discuss precautions that may avert Cannabis-associated harm

151145 AM – 12 PM: Cannabis and Opioid Interactions with Dr. Dustin Sulak, DO      

Propose medical Cannabis as an alternative to opioids for pain management

  1. Discuss the overlap between the endogenous opioid and endocannabinoid systems
  2. Justify the use of cannabis products including THC and CBD in various pain models
  3. Examine dosing schedules that reduce opioid use to promote multimodal pain management

1215 PM – 1230 PM: Case Discussion #1: Palliative Care 

Design safe and effective palliative care regimens for complex patient presentations

  1. Explain potential disease-state interactions with cannabinoids and formulations
  2. Develop appropriate initial recommendations for cannabis-naïve and experienced patients

1230 PM – 130 PM: Lunch 

130 PM – 2 PM:  Exhibitor Break

2 PM – 230 PM: Managing Cannabinoid Toxicity with Dr. Melani Kane, PharmD  

Review and resolve medication therapies for potential toxicity

  1. Define cannabinoid-specific and formulation-specific adverse reactions
  2. Outline potential strategies to mitigate cannabinoid medicine toxicity

230 PM – 330 PM:  Cannabis in Neurological Disorders with Dr. Stacia Woodcock, PharmD

Evaluate the role of phytocannabinoids in various degenerative and non-degenerative neurological disorders

  1. Summarize the literature surrounding medical cannabis in neurological disorders including; Multiple Sclerosis, Amyotrophic lateral sclerosis (ALS), Parkinson’s disease, Huntington’s disease, Tourette’s syndrome, Alzheimer’s, Autism, Epilepsy, Chronic Traumatic Encephalopathy (CTE), and PTSD
  2. Demonstrate the benefit versus risk of phytocannabinoids in various neurological disorders
  3. Relate the pharmacologic actions of phytocannabinoids to conventional therapies in neurological disorders

330 PM – 4 PM: Exhibitor Break      

4 PM – 430 PM: Cannabis in GI Disorders with Mr. Brian Essenter, RPh  

 Outline the role of cannabis medicine in gastrointestinal disorders

  1. Summarize the literature evaluating medical Cannabis in Crohn’s disease, ulcerative colitis, IBS, and liver disease
  2. Evaluate the use of common formulations in G/J tubes

430 PM – 5 PM: Cannabis in Immunology with Dr. Christine Roussel, PharmD, BCOP

Identify the intricate relationship between the ECS and the immune system

  1. Illustrate the role of the ECS in inflammatory conditions including psoriasis, solid organ transplant, bone marrow transplant, and rheumatoid arthritis
  2. Demonstrate the potential interaction between Cannabis products and immunomodulators

5 PM – 515 PM: Patient Consultations; Osteopathic Perspective with Dr. Dustin Sulak, DO 

Integrate medical Cannabis as a complementary or alternative therapy

  1. Develop a care plan for presenting patients from an osteopathic perspective

515 – 530 PM: Patient Consultations; Pharmacist Perspective with Dr. Shane Carmichael, PharmD

Integrate medical Cannabis as a complementary or alternative therapy

  1. Develop a care plan for presenting patients from a pharmacist perspective

530 PM – 6 PM: Case Discussion #2: Complex Patient Presentations 

Design safe and effective treatment regimens for complex patient presentations

  1. Formulate appropriate initial recommendations for cannabis-naïve and experienced patients
  2. Construct alternative recommendations for patients experiencing formulation-specific or cannabinoid-specific adverse reactions

>>> Conclusion of Day 1 Continuing Education accredited activities

6 PM – 7 PM:  Exhibitor Sponsored Cocktail Hour

7 PM – 9 PM:  Dinner  

SATURDAY, AUGUST 15, 2020 

630 AM – 730 AM: Breakfast  

730 AM – 815 AM: Special Populations: Pregnancy and Lactation with Dr. Laura Borgelt, PharmD  

Evaluate the use of medical Cannabis in special populations including pregnancy and lactation

  1. Explain the role of the ECS during prenatal and perinatal phases
  2. Interpret the risk of cannabis products for developing bodies
  3. Analyze the presence of cannabinoids in breast milk following maternal consumption

815 AM – 9 AM: Special Populations: Pediatrics with Dr. Bonni Goldstein, MD  

Evaluate the use of medical Cannabis in special populations including pediatrics and young adults  

  1. Identify potential pediatric conditions that could benefit from the use of medical Cannabis
  2. Compare the benefits and risks of phytocannabinoids; THC, CBD, CBG, CBN, and THCV in pediatric populations
  3. Construct initial dosing recommendations for pediatric patients with cancer, autism, pain, and epilepsy

9 AM – 930 AM: Special Populations: Geriatrics with Dr. Dustin Sulak, DO

Evaluate the use of medical Cannabis in special populations including geriatrics

  1. Summarize the risks of medical Cannabis in geriatric populations
  2. Develop dosing algorithms for cannabis-naïve elderly patients

930 AM – 1030 AM: Exhibitor Break  

1030 AM – 1130 AM: Psychiatric Considerations with TBD    

Explain the neuropsychiatric implications of Cannabis use in various populations

  1. Identify the association of neurocognitive impairment in adolescent versus adult populations
  2. Compare functional MRI (fMRI) scans in recreational and medical Cannabis users and the implications to prevent harm
  3. Summarize the findings of the National Academy of Sciences, Engineering, and Medicine related to the development of Cannabis-induced anxiety, depression, schizophrenia, and bipolar mania.

1130 AM – 1145 AM: Mindfulness Techniques with TBD 

1145 AM – 1230 PM:  Panel: Future of Cannabis Pharmacy Moderated by Dr. Jeff Lombardo, PharmD, BCOP with TBD

Interpret the future of Cannabis medicine and the role of the pharmacist

  1. Explain the current legal landscape and regulatory challenges of Cannabis across the United States and Canada
  2. Summarize the role of the 2018 Farm Bill and the implications for hemp–based products
  3. Identify challenges to standardization of medical products across state/country lines
  4. Predict the future of Cannabis pharmacy and the implications for the role of the pharmacist

1230 PM – 1 PM: Patient Case #3: Special Populations

Design safe and effective palliative care regimens for special populations including pediatrics and geriatrics  

  1. Formulate appropriate initial recommendations for sensitive populations including pediatrics and geriatrics
  2. Construct alternative recommendations for patients experiencing formulation-specific or cannabinoid-specific adverse reactions

>>> Conclusion of Day 2 Continuing Education accredited activities

1 PM – 2 PM: Optional Focus Group Opportunities